Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: Implication in 5-fluorouracil-based chemotherapy

Clinical Cancer Research

Volumn 3, Issue 3, 1997, Pages 395-399

  Jiang, Wenqi ^a,b   Lu, Zhihong ^a   He, Youjian ^b   Diasio, Robert B ^a  

^a University of Alabama at Birmingham   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CHINA; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; OXIDOREDUCTASES; PROGNOSIS;

EID: 0030988930     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Chabner, B. A., and Myers, C. E. Clinical pharmacology of cancer chemotherapy. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Cancer - Principles and Practice of Oncology, pp. 349-395. Philadelphia: J. B. Lippincott, 1989.
2. Diasio, R. B., and Harris B. E. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet., 16: 215-237, 1989.
3. Heggie, G. D., Sommadossi, J-P., Cross, D. S., Huster, W. J., and Diasio, R. B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res., 47: 2203-2206, 1987.
4. Harris, B. E., Song, R., He, Y-J., Soong, S-J., and Diasio, R. B. Circadian rhythm of rat liver dihydropyrimidine dehydrogenase, possible relevance to fluoropyrimidine chemotherapy. Biochem. Pharmacol., 37: 4759-4762, 1988.
5. Zhang, R., and Diasio, R. B. Pharmacologic basis for circadian pharmacodynamics. In: W. J. M. Hrushesky (ed.), Circadian Cancer Therapy, PP. 61-103. Boca Raton, FL: CRC Press, 1994.
6. Harris, B. E., Song, R., Soong, S-J., and Diasio, R. B. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res., 50: 197-201, 1990.
7. Levi, F., Misset, J-L., Brienza, S., Adam, R., Metzger, G., Itzakhi, M., Caussanel, J-P., Kunstlinger, F., Lecouturier, S., Descorps-Declere, A., Jasmin, C., Bismuth, H., and Reinberg, A. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. Cancer (Phila.), 69: 893-900, 1992.
8. Tuchman, M., Stoeckeler, J. S., Kiang, D. T., O'Dea, R. F., Rammaraine, M. L., and Mirkin, B. L. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N. Engl. J. Med., 313: 245-249, 1985.
9. Diasio, R. B., Beavers, T. L., and Carpenter, J. T. Familial deficiency of dihydropyrimidine dehydrogenase. J. Clin. Invest., 81: 47-51, 1988.
10. Harris, B. E., Carpenter, J. T., and Diasio, R. B. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: a potentially more common pharmacogenetic syndrome. Cancer (Phila.), 68: 499-501, 1991.
11. Lyss, A. P., Lilenbaum, R. C., Harries, B. E., and Diasio, R. B. Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity. Cancer Invest., 11: 239-240, 1993.
12. Lu, Z., Zhang, R., and Diasio, R. B. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res., 53: 5433-5438, 1993.
13. Houyan, P., Gay, C., Chatelut, E., Canal, P., and Milano, G. Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency. J. Natl. Cancer Inst., 85: 1602-1603, 1993.
14. Diasio, R. B., Van Kuilenburg, A. B., Lu, Z., Zhang, R., Van Lenthe, H., Bakker, H. D., and Van Gennip, A. H. Determination of dihydropyrimidine dehydrogenase (DPD) in fibroblasts of a DPD deficient pediatric patient and family members using a polyclonal antibody to human DPD. Adv. Exp. Med. Biol., 370: 7-10, 1994.
15. Goldberg, J. A., Kerr, D. J., Willmott, N., McKillop, J. H., and McArdle, C. S. Pharmacokinetics and pharmacodynamics of locoregional 5-fluorouracil (5-FU) in advanced colorectal liver metastases. Br. J. Cancer, 57: 186-189, 1988.
16. Fleming, R. A., Milano, G., Thyss, A., Etienne, M-C, Renee, N., Schneider, M., and Demard, F. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res., 52: 2899-2902, 1992.
17. Etienne, M. C., Lagrange, J. L., Dassonville, O., Fleming, R., Thyss, A., Renee, N., Schneider, M., Demard, F., and Milano, G. A population study of dihydropyrimidine dehydrogenase in cancer patients. J. Clin. Oncol., 12: 2248-2253, 1994.
18. Milano, G., Etienne, M. C., Casssuto-Viguier, E., Thyss, A., Santini, J., Frenay, M., Renee, N., Schneider, M., and Demard, F. Influence of sex and age on fluorouracil clearance. J. Clin. Oncol., 10: 1171-1175, 1992.
19. Ho, D. H., Townsend, L., Luma, M. A., and Bodely, G. P. Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res., 6: 781-784, 1986.
20. Naguib, F, N. M., el Kouni, M. H., and Cha, S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res., 45: 5405-5412, 1985.
21. Lu, Z., Zhang, R., and Diasio, R. B. Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Clin. Pharmcol. Ther., 58: 512-522, 1995.
22. Reichard, O., Skold, O., Klein, G., Revesz, L., and Magnusson, P. H. Studies on resistance against 5-fluorouracil. Enzymes of the uracil pathway during development of resistance. Cancer Res., 22: 235-243, 1962.
23. Ardalan, B., Cooney, D. A., Jayaram, H. N., Carrico, C. K., Glazer, R. I., MacDonald, J., and Schein, P. S. Mechanisms of sensitivity and resistance of murine tumors to 5-fluorouracil. Cancer Res., 40: 1431-1437, 1980.
24. Grem, J. L. Fluorinated pryrimidine. In: B. A. Chabner and J. M. Collins (eds.), Cancer Chemotherapy, Principles and Practice, pp. 180-225. Philadelphia: J. B. Lippincott, 1990.
25. Parker, W. B., and Cheng, Y. C. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol. Ther., 48: 381-395, 1990.
26. Beck, A., Etienne, M. C., Cheradame, S., Fischel, J. L., Formento, P., Renee, N., and Milano, G. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil. Eur. J. Cancer, 30A: 1517-1522, 1994.
27. Etienne, M. C., Cheradame, S., Fischel, J. L., Dassonville, O., Renee, N., Schneider, M., Thyss, A., Demard, F., and Milano, G. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J. Clin. Oncol., 13: 1663-1670, 1995.
28. Wanebo, H. J., Falkson, G., and Order, S. E. Cancer of hepatobilliary system. In: V. T. Devita, S. Hellman, and S. A. Rosenberg (eds.), Cancer-Principles and Practice of Oncology, pp. 836-874. Philadelphia: J. B. Lippincott, 1989.
29. Sommadossi, J-P., Gewirtz, D. A., Diasio, R. B., Aubert, C., Cano, J. P., and Goldman, I. D. Rapid catabolism of 5-fluorouracil in freshly isolated hepatocytes as analyzed by high performance liquid chromatography. J. Biol. Chem., 257: 8171-8176, 1982.
30. Bradford, M. A. Rapid sensitive method for the quantitation of microgram qualities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1976.
31. Naguib, F. N. M., Hao, S. N., and el Kouni, M. H. Potentiation of 5-fluorouracil efficacy by the dihydropyrimidine dehydrogenase inhibitor, 5-benzyloxybenzyluracil. Cancer Res., 54: 5166-5170, 1994.
32. Cao, S., Rustum, Y. M., and Spector, T. 5-ethynyluracil (776C85): modulation of 5- fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res., 54: 1507-1510, 1994.
33. Fischel, J. L., Etienne, M. C., Spector, T., Formento, P., Renee, N., and Milano, G. Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation. Clin. Cancer Res., 1: 991-996, 1995.